Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to learn if giving rituximab, the study drug, right
into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.